Keymed Biosciences (HKSE:02162) Long-Term Debt : HK$375.33 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Keymed Biosciences Long-Term Debt?

Keymed Biosciences's Long-Term Debt for the quarter that ended in Jun. 2024 was HK$375.33 Mil.

Keymed Biosciences's quarterly Long-Term Debt increased from Jun. 2023 (HK$296.53 Mil) to Dec. 2023 (HK$362.95 Mil) and increased from Dec. 2023 (HK$362.95 Mil) to Jun. 2024 (HK$375.33 Mil).

Keymed Biosciences's annual Long-Term Debt increased from Dec. 2021 (HK$0.00 Mil) to Dec. 2022 (HK$32.16 Mil) and increased from Dec. 2022 (HK$32.16 Mil) to Dec. 2023 (HK$362.95 Mil).

Keymed Biosciences Long-Term Debt Historical Data

The historical data trend for Keymed Biosciences's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keymed Biosciences Long-Term Debt Chart

Keymed Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

32.16

362.95

Keymed Biosciences Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Long-Term Debt	Get a 7-Day Free Trial					11.72	32.16	296.53	362.95	375.33

Keymed Biosciences (HKSE:02162) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Keymed Biosciences Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Keymed Biosciences's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Keymed Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keymed Biosciences Inc (HKSE:02162) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

64Z:Germany

Address

No. 18 BioTown Middle Road, Building D2, Tianfu International BioTown, Chengdu, Sichuan, CHN, 610219

Website

https://www.keymedbio.com

Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.

Executives

Chen Bo	2201 Interest of corporation controlled by you
Eagle Hero Management Limited	2101 Beneficial owner
Trident Trust Company (hk) Limited	2301 Trustee
Moonshot Holdings Limited	2101 Beneficial owner
Hh Kny Holdings Limited
Hillhouse Investment Management, Ltd.
Boyu Capital Group Holdings Ltd
Xyxy Holdings Ltd.
Tong Xiaomeng

Keymed Biosciences Headlines

No Headlines